

Quikflo Health Inc.  
711 Alastair Ross  
Technology Centre,  
3553 31 Street NW.



---

## QuikFlo Secures Frankfurt Stock Exchange Listing

**Calgary, Alberta, December 30, 2015 – QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSXV:QF)(FRANKFURT:1QF)** is pleased to announce the listing of its common shares on the Frankfurt Stock Exchange under the symbol "1QF". The company's common shares now trade concurrently on the Frankfurt Stock Exchange with the TSX Venture Exchange under the symbol "QF".

The Frankfurt Stock Exchange is one of the world's largest exchanges with significant liquidity and a large investor base. Listing on the Frankfurt Stock Exchange will give QuikFlo exposure to a much larger investor base. The company's Frankfurt Profile can be viewed here: [http://en.boerse-frankfurt.de/stock/QuikFlo\\_Health-Share](http://en.boerse-frankfurt.de/stock/QuikFlo_Health-Share)

Vinny Jindal, President and CEO, stated: "This listing is exciting for our young company to increase awareness to European investors and aid in telling QuikFlo's exciting story at an international level."

### About QuikFlo

QuikFlo Health is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

### Further Information

For further information relating to the Company or this release please visit [www.sedar.com](http://www.sedar.com), [www.quikflohealth.com](http://www.quikflohealth.com), or contact Vinny Jindal, President and CEO at 646.526.9628 or Investor Relations for the Company at 647.980.7541.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

## **Cautionary and Forward-Looking Statements**

*This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this news release contains forward-looking statements and information relating to the Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the suitability of the key members of ongoing management and the board of directors, the commercial opportunities available to the Company based on the technology acquired, and the ability of the Company to obtain sufficient funds to commercialize any product. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.*

*Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on [www.sedar.com](http://www.sedar.com). Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties is set forth in the circular.*

*The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.*